Motility & Functional GI · Article 133

Which IBS Therapies Should Be Chosen for IBS-C Versus IBS-D?

IBS-C IBS-D treatment requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

IBS-C IBS-D treatment clinical reference — Related free clinical resource: Clinical Pharmacology.

IBS-C IBS-D treatment: practical clinical approach

This page focuses on IBS-C IBS-D treatment with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for IBS-C IBS-D treatment

Clinical takeaway: For IBS-C IBS-D treatment, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: IBS treatment should be subtype- and symptom-directed. IBS-C often responds to soluble fiber and agents that increase intestinal secretion such as linaclotide, plecanatide or lubiprostone; tenapanor and selected prokinetic/5-HT4 strategies may also be options depending on region. IBS-D treatments include rifaximin, eluxadoline in appropriately selected patients, loperamide for diarrhea control, and selected neuromodulators. Both subtypes can benefit from low-FODMAP dietary therapy and gut-directed psychotherapy.

IBS-C

Soluble fiber is reasonable first-line when tolerated. Secretagogues improve stool frequency and global symptoms. Therapy choice depends on pain burden, cost, access and adverse effects.

IBS-D

Rifaximin has evidence for global symptoms. Eluxadoline is contraindicated in patients without a gallbladder and in other high-risk groups. Loperamide improves stool frequency/urgency but has weaker evidence for global IBS symptom relief.

Pain and gut-brain symptoms

Tricyclic antidepressants can be particularly useful when pain and diarrhea coexist. Gut-directed psychotherapy is evidence based and should not be framed as treatment of an imaginary illness.

Practical clinical algorithm

Classify predominant stool pattern using current symptoms.
Identify the dominant problem: pain, constipation, diarrhea, bloating or urgency.
Use subtype-specific drug therapy.
Layer diet and gut-brain treatment when appropriate.
Reassess efficacy after a defined trial and switch rather than endlessly stacking ineffective drugs.

Common mistakes to avoid

Using insoluble bran in a highly bloated IBS patient.
Giving eluxadoline to a patient without a gallbladder.
Using loperamide as though it treats all global IBS symptoms.
Ignoring pain when selecting constipation therapy.
Using opioids for IBS pain.

Trainee takeaway

IBS-C and IBS-D share a diagnosis but not a drug algorithm; choose therapy around stool pattern and the symptom that most impairs the patient.

Frequently asked questions

Does fiber help IBS-C?

Soluble fiber, such as psyllium, is more consistently useful than insoluble bran.

What drug has strong evidence for IBS-D global symptoms?

Rifaximin is one evidence-supported option.

Can psychological therapy help bowel symptoms?

Yes. Gut-directed therapies improve global IBS symptoms in appropriately selected patients.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Practice Review in Gastroenterology. CAPstone Academic Publishers; 2014.

3. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116:17-44.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions